Skip to content

Rigel Pharmaceuticals

US · RIGL #3318 by market cap
40.09 -1.10 -2.67%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 40.50 -1.68%
After-hours 40.00 -0.22%
51.4529.1740.092026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RIGL?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is -10.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has fallen to 13.6% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall A+
ValuationGrowthProfitMomentumHealthAnalyst
Valuation B+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 2.5x Better than 99%
Forward P/E 12.0x Better than 68%
Price / Sales 2.9x Better than 43%
P/E vs own 5-yr range 70th pctl Better than 37%
Growth A+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 34.8% Better than 92%
Free cash flow CAGR (3Y) 80.9% Better than 91%
Profitability A+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 93.3% Better than 98%
Operating margin 42.6% Better than 96%
Net margin 124.7% Better than 100%
Return on equity 185.9% Better than 98%
Return on invested capital 145.6% Better than 100%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -12.6% Better than 45%
6-month return 38.2% Better than 93%
12-month return (ex latest month) 4.1% Better than 39%
Distance below 52-week high 23.8% Better than 53%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.4x Better than 65%
Debt to assets 10.4% Better than 69%
Interest coverage 17.6x Better than 81%
Free cash flow / net income 20.6% Better than 6%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 50.0% Better than 26%
Upside to average target 66.5% Better than 75%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -9.83%
1M -16.67%
3M -11.40%
6M +39.10%
YTD -6.40%
1Y -8.55%
3Y +326.49%
5Y +31.44%

Key statistics

Price & volume

Prev close
41.19
Open
40.65
Day range
39.62 - 41.66
Avg price
40.26
Volume
352.23K
Turnover
14.18M
Amplitude
4.96%
52-week range
24.95 - 52.61

Valuation

P/E
2.06
P/E (TTM)
2.49
P/B
1.70
EPS
19.48
Net profit
366.81M
Net assets
445.10M

Share structure

Market cap
754.89M
Float cap
606.40M
Shares out
18.83M
Float shares
15.13M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 55% of range
24.95 52.61

23.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+2.11M net over the window

Short interest

Shares short
2.54M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Rigel Pharmaceuticals (RIGL)?

Rigel Pharmaceuticals last traded at 40.09. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Rigel Pharmaceuticals's market cap?

About 754.89M.

What is the P/E ratio of Rigel Pharmaceuticals?

The trailing twelve-month P/E is 2.49, above its own 5-year average of 1.07 — toward the top of its historical range (70.39% percentile). See the Valuation tab for the full history.

Does Rigel Pharmaceuticals pay a dividend?

Rigel Pharmaceuticals does not currently pay a regular dividend.

Is Rigel Pharmaceuticals a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 66.75, which implies 66.5% upside from the current price. This is not investment advice.

What is Rigel Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Rigel Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Rigel Pharmaceuticals discussion 0 comments

Add a comment